Impaired amyloid β-degrading enzymes in brain of streptozotocin- induced diabetic rats

Journal of Endocrinological Investigation

Volumn 34, Issue 1, 2011, Pages 26-31

  Liu, Y ^a,b   Liu, L ^a   Lu, S ^a   Wang, D ^a   Liu, Xiao Dong ^a   Xie, L ^a   Wang, G ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Amyloid peptide; Diabetes mellitus; Endothelin converting enzyme 1; Insulin degrading enzyme; Neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; ENDOTHELIN CONVERTING ENZYME; INSULINASE; ISOPHANE INSULIN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; MALE; NONHUMAN; PROTEIN DEGRADATION; RAT; STREPTOZOCIN DIABETES; TEMPORAL CORTEX;

AMYLOID BETA-PEPTIDES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BRAIN; DIABETES MELLITUS, EXPERIMENTAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INSULYSIN; MALE; METALLOENDOPEPTIDASES; NEPRILYSIN; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TISSUE DISTRIBUTION;

EID: 79955429140     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346691     Document Type: Article

References (40)

1. Saido TC. Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging 1998, 19 (1 Suppl): S69-75.
2. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 2008, 18: 240-52. (Pubitemid 351436347)
3. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res 2008, 5: 212-24. (Pubitemid 351536346)
4. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43: 605-8. (Pubitemid 39179722)
5. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today 2006, 11: 931-8.
6. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 2005, 26: 645-54. (Pubitemid 40228756)
7. Cook DG, Leverenz JB, McMillan PJ, et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003, 162: 313-9. (Pubitemid 36042013)
8. Farris W, Mansourian S, Leissring MA, et al. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 2004, 164: 1425-34. (Pubitemid 38387808)
9. Funalot B, Ouimet T, Claperon A, et al. Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease. Mol Psychiatry 2004, 9: 1122-8, 1059. (Pubitemid 40065446)
10. Mouri A, Zou LB, Iwata N, et al. Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. Behav Brain Res 2006, 168: 83-91. (Pubitemid 43152056)
11. Newell AJ, Sue LI, Scott S, et al. Thiorphan-induced neprilysin inhibition raises amyloid beta levels in rabbit cortex and cerebrospinal fluid. Neurosci Lett 2003, 350: 178-80. (Pubitemid 37205194)
12. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005, 19: 127-35. (Pubitemid 40409531)
13. Eckman EA, Adams SK, Troendle FJ, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006, 281: 30471-8. (Pubitemid 44582103)
14. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292: 1550-2. (Pubitemid 32493424)
15. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003, 278: 2081-4. (Pubitemid 36801269)
16. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100: 4162-7. (Pubitemid 36418174)
17. Miller BC, Eckman EA, Sambamurti K, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci USA 2003, 100: 6221-6. (Pubitemid 36576957)
18. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002, 51: 1256-62.
19. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tanihara H. Vitreous fluid levels of beta-amyloid(1-42) and tau in patients with retinal diseases. Jpn J Ophthalmol 2005, 49: 106-8. (Pubitemid 40603154)
20. Li ZG, Zhang W, Sima AA. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56: 1817-24. (Pubitemid 47025451)
21. Liu Y, Liu H, Yang J, et al. Increased amyloid beta-peptide (1-40) level in brain of streptozotocin-induced diabetic rats. Neuroscience 2008, 153: 796-802.
22. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiology of Aging 2006, 27: 190-8. (Pubitemid 43038542)
23. Choi DS, Wang D, Yu GQ, et al. PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc Natl Acad Sci USA 2006, 103: 8215-20. (Pubitemid 43801078)
24. Zhao Z, Xiang Z, Haroutunian V, Buxbaum JD, Stetka B, Pasinetti GM. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol Aging 2007, 28: 824-30. (Pubitemid 46589743)
25. Fernandez D, Valdivia A, Irazusta J, Ochoa C, Casis L. Peptidase activities in human semen. Peptides 2002, 23: 461-8.
26. Lopez-Ongil S, Saura M, Zaragoza C, et al. Hydrogen peroxide regulation of bovine endothelin-converting enzyme-1. Free Radic Biol Med 2002, 32: 406-13. (Pubitemid 34178350)
27. Havrankova J, Roth J, Brownstein MJ. Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J Clin Invest 1979, 64: 636-42. (Pubitemid 9235011)
28. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004, 62: 925-31. (Pubitemid 38435780)
29. Taguchi K, Yamagata HD, Zhong W, et al. Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann Neurol 2005, 57: 585-8. (Pubitemid 40471174)
30. Turner AJ, Murphy LJ. Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol 1996, 51: 91-102. (Pubitemid 26020684)
31. Yasojima K, Akiyama H, McGeer EG, McGeer PL. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 2001, 297: 97-100.
32. Hellstrom-Lindahl E, Ravid R, Nordberg A. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. Neurobiol Aging 2008, 29: 210-21.
33. Pardossi-Piquard R, Petit A, Kawarai T, et al. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron 2005, 46: 541-54. (Pubitemid 40797380)
34. Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A. Neprylisin decreases uniformly in Alzheimer's disease and in normal aging. FEBS Lett 2005, 579: 6027-30. (Pubitemid 41546241)
35. Wang DS, Lipton RB, Katz MJ, et al. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropath Exp Neur 2005, 64: 378-85. (Pubitemid 40629127)
36. Cordes CM, Bennett RG, Siford GL, Hamel FG. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem Pharmacol 2009, 77: 1064-73.
37. Kim M, Hersh LB, Leissring MA, et al. Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem 2007, 282: 7825-32. (Pubitemid 47093556)
38. Zhao L, Teter B, Morihara T, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004, 24: 11120-6. (Pubitemid 40012971)
39. Hong H, Liu LP, Liao JM, et al. Downregulation of LPR1 at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology 2009, 56: 1054-9.
40. Liu LP, Hong H, Liao JM, et al. Upregulation of RAGE at the blood-brain barrier in streptozotocin-induced diabetic mice. Synapse 2009, 63: 636-42.